Pfizer's stock remains stable amid strategic shift and AI healthcare focus.

Pfizer is navigating a post-pandemic landscape by refocusing on its core pharmaceutical portfolio, including oncology, vaccines, and internal medicine. The company is also exploring opportunities in AI healthcare to enhance diagnostics and treatment decisions. Despite these strategic shifts, there have been no significant market-moving developments in the past 24 hours.

AI-generated from public news sources. Not financial advice.